Canada Recommends Public Coverage for Alzheimer’s Drug in Policy Reversal
Canada’s Drug Agency has reversed its initial stance, now recommending that public drug plans provide coverage for the Alzheimer’s medication lecanemab, provided specific clinical and safety conditions are met. The Canadian Drug Expert Committee (CDEC) updated its recommendation on Thursday, citing new evidence and a pressing clinical need, despite lingering concerns over the drug’s high … Read more